Rongchang Bio’s stock price surged as the Phase III clinical trial of Telitacicept for gMG in China was selected for an oral presentation at the 2025 AANEM.
$REMEGEN (09995.HK)$ The stock surged over 8% at the opening session. As of the time of writing, it was up 5.65%, trading at HKD 112.2 with a turnover of HKD 254 million.
In terms of news, on September 18, Rongchang Bio announced that Telitacicept (RC18, trade name: Tai’ai), an innovative drug developed in-house as a world-first dual-target fusion protein targeting BLyS/APRIL for the treatment of generalized myasthenia gravis (gMG), had its China Phase III clinical trial data selected for oral presentation at the 2025 annual meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM). The data includes the 48-week open-label extension study (OLE) used to verify long-term efficacy. The annual meeting will…
